Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with …
HJM Groen, H Sietsma, A Vincent… - Journal of clinical …, 2011 - ascopubs.org
Purpose Cyclooxygenase-2 (COX-2) protein expression in patients with non–small-cell lung
cancer (NSCLC) may be not only a prognostic marker but also predictive for COX-2 …
cancer (NSCLC) may be not only a prognostic marker but also predictive for COX-2 …
[引用][C] Randomized, Placebo-Controlled Phase III Study of Docetaxel Plus Carboplatin With Celecoxib and Cyclooxygenase-2 Expression As a Biomarker for Patients …
HJM GROEN, H SIETSMA… - Journal of clinical …, 2011 - pascal-francis.inist.fr
Author GROEN, Harry J. M 1; SIETSMA, Hannie 1; HILTERMANN, T. Jeroen N 1; VAN DEN
BORNE, Ben EE M 8; SCHRAMEL, Franz MN H 9; VINCENT, Andrew 3; HOCHSTENBAG …
BORNE, Ben EE M 8; SCHRAMEL, Franz MN H 9; VINCENT, Andrew 3; HOCHSTENBAG …
Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with …
HJM Groen, H Sietsma, A Vincent… - Journal of Clinical …, 2011 - research.sahmri.org.au
Purpose: Cyclooxygenase-2 (COX-2) protein expression in patients with non-small-cell lung
cancer (NSCLC) may be not only a prognostic marker but also predictive for COX-2 …
cancer (NSCLC) may be not only a prognostic marker but also predictive for COX-2 …
[引用][C] Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with …
H Groen, A Vincent, M Hochstenbag, J van Putten… - 2011 - digital.library.adelaide.edu.au
Adelaide Research & Scholarship: Randomized, placebo-controlled phase III study of docetaxel
plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients …
plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients …
[PDF][PDF] Randomized, Placebo-Controlled Phase III Study of Docetaxel Plus Carboplatin With Celecoxib and Cyclooxygenase-2 Expression As a Biomarker for Patients …
HJM Groen, H Sietsma, A Vincent, MMH Hochstenbag… - Oncology, 2009 - researchgate.net
Purpose Cyclooxygenase-2 (COX-2) protein expression in patients with non–small-cell lung
cancer (NSCLC) may be not only a prognostic marker but also predictive for COX-2 …
cancer (NSCLC) may be not only a prognostic marker but also predictive for COX-2 …
Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with …
HJ Groen, H Sietsma, A Vincent… - Journal of Clinical …, 2011 - europepmc.org
Purpose Cyclooxygenase-2 (COX-2) protein expression in patients with non-small-cell lung
cancer (NSCLC) may be not only a prognostic marker but also predictive for COX-2 …
cancer (NSCLC) may be not only a prognostic marker but also predictive for COX-2 …
Randomized, Placebo-Controlled Phase III Study of Docetaxel Plus Carboplatin With Celecoxib and Cyclooxygenase-2 Expression As a Biomarker for Patients With …
HJM Groen, H Sietsma, A Vincent… - Journal of Clinical …, 2011 - cris.maastrichtuniversity.nl
Abstract Cyclooxygenase-2 (COX-2) protein expression in patients with non-small-cell lung
cancer (NSCLC) may be not only a prognostic marker but also predictive for COX-2 …
cancer (NSCLC) may be not only a prognostic marker but also predictive for COX-2 …
Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with …
HJM Groen, H Sietsma, A Vincent… - Journal of clinical …, 2011 - pubmed.ncbi.nlm.nih.gov
Purpose Cyclooxygenase-2 (COX-2) protein expression in patients with non-small-cell lung
cancer (NSCLC) may be not only a prognostic marker but also predictive for COX-2 …
cancer (NSCLC) may be not only a prognostic marker but also predictive for COX-2 …
Randomized, Placebo-Controlled Phase III Study of Docetaxel Plus Carboplatin With Celecoxib and Cyclooxygenase-2 Expression As a Biomarker for Patients With …
HJM Groen, H Sietsma, A Vincent… - Journal of Clinical …, 2011 - research.rug.nl
Purpose Cyclooxygenase-2 (COX-2) protein expression in patients with non-small-cell lung
cancer (NSCLC) may be not only a prognostic marker but also predictive for COX-2 …
cancer (NSCLC) may be not only a prognostic marker but also predictive for COX-2 …